We are really struggling with maintaining effective therapeutic options for high-risk patients with COVID-19. Particularly because the monoclonal antibody treatments we had been using and relying on for the past year-and-a-half are no longer effective against recent Omicron subvariants because the virus has changed."
Adit Ginde, MD, professor of emergency medicine, University of Colorado School of Medicine